Dr. Betz is a founder of Crinetics. Prior to Crinetics, he was director of endocrinology and metabolism at Neurocrine Biosciences and worked on the discovery and development of GnRH receptor antagonists and nonpeptide modulators of other endocrine targets. Prior to Neurocrine, he led laboratory efforts at GeneFormatics, and at Abbott Laboratories worked in pharmaceutical discovery, including structure-guided drug design, assay development, and compound screening in the Research NMR Group. He holds a B.S. in chemistry from the University of Delaware and Ph.D. in chemistry from the University of North Carolina at Chapel Hill.
Nonpeptide gonadotropin-releasing hormone receptor antagonists.
Betz SF, Zhu YF, Chen C, Struthers RS. Journal of Medicinal Chemistry. 2008; 51:3331-48.
Allosteric and orthosteric binding modes of two nonpeptide human gonadotropin-releasing hormone receptor antagonists.
Sullivan SK, Brown MS, Gao Y, Loweth CJ, Lio FM, Crowe PD, Struthers RS, Betz SF. Biochemistry. 2006; 45:15327-37.
Overlapping, nonidentical binding sites of different classes of nonpeptide antagonists for the human gonadotropin-releasing hormone receptor.
Betz SF, Reinhart GJ, Lio FM, Chen C, Struthers RS. Journal of Medicinal Chemistry. 2006; 49:637-47.
Determination of the binding mode of thienopyrimidinedione antagonists to the human gonadotropin releasing hormone receptor using structure-activity relationships, site-directed mutagenesis, and homology modeling.
Betz SF, Lio FM, Gao Y, Reinhart GJ, Guo Z, Mesleh MF, Zhu YF, Struthers RS. Journal of Medicinal Chemistry. 2006; 49:6170-6.